Details for Patent: 10,973,827
✉ Email this page to a colleague
Which drugs does patent 10,973,827 protect, and when does it expire?
Patent 10,973,827 protects JENTADUETO and is included in one NDA.
Protection for JENTADUETO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-eight patent family members in twenty-eight countries.
Summary for Patent: 10,973,827
Title: | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Abstract: | The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases. |
Inventor(s): | Friedl; Thomas (Ochsenhausen, DE), Braun; Michael (Senden, DE), Egusa; Kenji (Biberach an der Riss, DE), Fujita; Hikaru (Osaka, JP), Maruyama; Megumi (Hyogo, JP), Nishioka; Takaaki (Kobe, JP) |
Assignee: | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) |
Application Number: | 16/676,643 |
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Dosage form; |
Drugs Protected by US Patent 10,973,827
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim | JENTADUETO | linagliptin; metformin hydrochloride | TABLET;ORAL | 201281-003 | Jan 30, 2012 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Boehringer Ingelheim | JENTADUETO | linagliptin; metformin hydrochloride | TABLET;ORAL | 201281-001 | Jan 30, 2012 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Boehringer Ingelheim | JENTADUETO | linagliptin; metformin hydrochloride | TABLET;ORAL | 201281-002 | Jan 30, 2012 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,973,827
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
08154039 | Apr 3, 2008 |
International Family Members for US Patent 10,973,827
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 071175 | ⤷ Try a Trial | |||
Australia | 2009232043 | ⤷ Try a Trial | |||
Brazil | PI0911273 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |